Original title: Stellite used more than half of the fixed increase funds to buy wealth management before the disclosure of its half-year results forecast.
China Net Finance, July 10 (Reporter Ye Qiandan Shengqun) On the evening of July 7, Stellite released the semi-annual performance forecast for 2022. During the reporting period, the company expects to achieve a net profit of 55 million to 75 million yuan attributable to the parent , a year-on-year decrease of 51.81%-64.66%.
Regarding the reasons for the decline in performance, Stellite said that in the first half of 2022, the upstream of the company’s main products was affected by rising raw material prices, and the downstream was affected by centralized procurement pricing, resulting in a decrease in gross profit margin during the reporting period compared with the same period last year; at the same time, due to the new crown Affected by the epidemic, the production and sales of preparations in Shanghai fell short of expectations, resulting in a decline in the company’s operating performance compared with the same period last year.
According to the data, Stellite is an enterprise engaged in the research and development, production and sales of characteristic raw materials (including intermediates) and product drugs, and is the largest and most complete non-ionic iodine contrast agent manufacturer in China.
It is worth noting that before the semi-annual results announcement, Stellite’s share price had experienced abnormal fluctuations. On July 5 and 6, Stellite’s share price fell by the limit for two consecutive days. On the 7th, Stellite issued an announcement on fluctuations in stock trading, stating that after self-examination, the company’s current production and operation activities are normal, the internal production and operation order is normal, and the company has no material information that should be disclosed but not disclosed.
According to the data of the Dragon Tiger List, on July 5, the net sales of special seats for 5 institutions was 613 million yuan; on the 6th, the special seats for 4 institutions and Shanghai Xietu Road seats of Changjiang Securities sold a total of 278 million yuan. The company’s stock price continued to drop by the limit before the pre-announcement of results, and the massive selling by institutions also attracted investors’ doubts.
Source: SSE e Interactive
In addition, in recent years, Stellite has used a large amount of funds to purchase wealth management products, including part of the idle raised funds.
In July 2020, Stellite privately issued 9,542,700 RMB ordinary shares (A shares) to 8 specific targets at an issue price of RMB 70.42 per share, raising a total of RMB 672 million, deducting underwriting and sponsorship fees. , After deducting the newly added external expenses directly related to the issuance of equity securities, the net amount of funds raised was 653 million yuan.
It is worth noting that the 653 million yuan fixed increase has just been put into the bag, and Stellite has passed two meetings successively, using a total of no more than 500 million yuan of idle raised funds for cash management, which is used for investment with high security and liquidity. financial products.
According to statistics, from September 28, 2020 to February 10, 2022, Stellite spent a total of 1.1 billion yuan to purchase wealth management products, and the maturity income (tax included) totaled 7.3408 million yuan.
As of December 31, 2021, the total balance of Stellite’s special account for raised funds was 288 million yuan. In addition, since February 10, 2022, Stellite has purchased bank wealth management products 5 times, and its wealth management funds are all from the idle funds raised by non-public issuance of stocks. Return to Sohu, see more
Editor:
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.